Source: Clinics. Unidades: HU, FM
Subjects: SÍNDROME DO OVÁRIO POLICÍSTICO (FISIOPATOLOGIA), FATORES DE CRESCIMENTO, INSULINA (RESISTÊNCIA), ANTROPOMETRIA, HIRSUTISMO (ETIOLOGIA)
ABNT
BATISTA, José Gomes et al. Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics, v. 67, n. 3, p. 283-287, 2012Tradução . . Disponível em: https://doi.org/10.6061/clinics/2012(03)14. Acesso em: 06 out. 2024.APA
Batista, J. G., Soares-Jr., J. M., Maganhin, C. C., Simões, R. S., Tomaz, G., & Baracat, E. C. (2012). Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics, 67( 3), 283-287. doi:10.6061/clinics/2012(03)14NLM
Batista JG, Soares-Jr. JM, Maganhin CC, Simões RS, Tomaz G, Baracat EC. Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study [Internet]. Clinics. 2012 ; 67( 3): 283-287.[citado 2024 out. 06 ] Available from: https://doi.org/10.6061/clinics/2012(03)14Vancouver
Batista JG, Soares-Jr. JM, Maganhin CC, Simões RS, Tomaz G, Baracat EC. Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study [Internet]. Clinics. 2012 ; 67( 3): 283-287.[citado 2024 out. 06 ] Available from: https://doi.org/10.6061/clinics/2012(03)14